Get the Stockscreener App
4.19
0.47%
-0.10
Vistagen Therapeutics Inc stock is traded at $4.19, with a volume of 98,944.
It is down -0.47% in the last 24 hours and up +2.15% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$4.29
Open:
$4.4
24h Volume:
98,944
Relative Volume:
0.15
Market Cap:
$167.86M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-3.1215
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-12.86%
1M Performance:
+2.15%
6M Performance:
+80.17%
1Y Performance:
+64.55%
1-Day Range:
$4.24
$4.42
1-Week Range:
$3.36
$4.909
52-Week Range:
$1.90
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
4.25 | 169.04M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.60 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
731.09 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.00 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
913.29 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.21 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Why Vistagen Therapeutics Inc. stock is trending among retail tradersJuly 2025 Final Week & Free Community Consensus Stock Picks - Newser
Will Vistagen Therapeutics Inc. stock pay special dividends2025 Year in Review & Reliable Entry Point Trade Alerts - Newser
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
VistaGen appoints Nick Tressler as CFO - MSN
Vistagen Appoints Nick Tressler as Chief Financial Officer - PharmiWeb.com
The time has not yet come to remove your chips from the table: Vistagen Therapeutics Inc (VTGN) - Setenews
Vistagen Therapeutics Appoints Nick Tressler as CFO - MarketScreener
Vistagen (VTGN) Appoints New CFO, Nick Tressler - GuruFocus
Vistagen (VTGN) Names Nick Tressler as New CFO - GuruFocus
Vistagen Names Nick Tressler as Chief Financial Officer - Contract Pharma
Vistagen appoints Nick Tressler as chief financial officer - marketscreener.com
Vistagen (Nasdaq: VTGN) appoints CFO Nick Tressler, grants 150,000-share option - Stock Titan
Why retail investors pile into Vistagen Therapeutics Inc. stock2025 Sector Review & Technical Pattern Based Signals - BỘ NỘI VỤ
Vistagen Therapeutics Inc. (VTGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vistagen (VTGN) Presents Promising Data on PH80 for Menopause Sy - GuruFocus
Vistagen presents data on PH80 for menopausal hot flashes treatment By Investing.com - Investing.com Canada
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting - Yahoo Finance
Form 8-KCurrent report - ADVFN
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update - ADVFN
What analysts say about Vistagen Therapeutics Inc stockTop Performing Stocks & Free ETF and Mutual Fund Comparisons - earlytimes.in
Is Vistagen Therapeutics Inc a good long term investmentTechnical Breakout Signals & High Return Capital Strategies - earlytimes.in
Can Vistagen Therapeutics Inc. stock hit analyst price targetsSwing Trade & Expert Verified Stock Movement Alerts - newser.com
What technical charts say about Vistagen Therapeutics Inc. stockJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - newser.com
Will Vistagen Therapeutics Inc. stock split attract more investorsJuly 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
ETFs Investing in Vistagen Therapeutics, Inc. Stocks - TradingView
Can Vistagen Therapeutics Inc. stock deliver surprise earnings beatQuarterly Market Review & Long Hold Capital Preservation Plans - newser.com
Will Vistagen Therapeutics Inc. stock deliver shareholder valueQuarterly Market Summary & Stepwise Entry and Exit Trade Signals - newser.com
How Vistagen Therapeutics Inc. stock compares to industry benchmarksQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Is Vistagen Therapeutics Inc. stock attractive for income investorsGold Moves & AI Driven Stock Movement Reports - newser.com
Is Vistagen Therapeutics Inc. a candidate for recovery play2025 Market Outlook & AI Forecast Swing Trade Picks - newser.com
Using RSI to spot recovery in Vistagen Therapeutics Inc.Market Performance Report & AI Powered Buy and Sell Recommendations - newser.com
Is Vistagen Therapeutics Inc. stock a safe haven assetBear Alert & Low Risk High Win Rate Stock Picks - newser.com
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 (NASDAQ:VTGN) - Seeking Alpha
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Stifel reiterates Buy rating on VistaGen stock, maintains $12 price target - Investing.com Nigeria
Vistagen Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Rallies & Low Drawdown Investment Strategies - newser.com
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):